Top

Journal of Cardiovascular Magnetic Resonance

Published in:

Open Access 01-12-2009 | Case report

Recovery of methamphetamine associated cardiomyopathy predicted by late gadolinium enhanced cardiovascular magnetic resonance

Authors: Javier E Lopez, Khung Yeo, Gary Caputo, Michael Buonocore, Saul Schaefer

Published in: Journal of Cardiovascular Magnetic Resonance | Issue 1/2009

Abstract

Methamphetamine is known to cause a cardiomyopathy which may be reversible with appropriate medical therapy and cessation of use. Late gadolinium enhancement cardiovascular magnetic resonance (CMR) has been shown to identify fibrosis in ischemic and non-ischemic cardiomyopathies. We present a case of severe methamphetamine-associated cardiomyopathy in which cardiac function recovered after 6 months. Evaluation by CMR using late gadolinium enhancement was notable for an absence of enhancement, suggesting an absence of irreversible myocyte injury and a good prognosis. CMR may be useful to predict recovery in toxin-associated non-ischemic cardiomyopathies.

Available only for authorised users

Wolkoff DA: Methamphetamine abuse: an overview for health care professionals. Hawaii Med J. 1997, 56: 34-36.PubMed

Diercks DB, Fonarow GC, Kirk JD, Jois-Bilowich P, Hollander JE, Weber JE, Wynne J, Mills RM, Yancy C, Peacock WF: Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am J Cardiol. 2008, 102: 1216-1219. 10.1016/j.amjcard.2008.06.045.CrossRefPubMed

Yeo KK, Wijetunga M, Ito H, Efird JT, Tay K, Seto TB, Alimineti K, Kimata C, Schatz IJ: The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007, 120: 165-171. 10.1016/j.amjmed.2006.01.024.CrossRefPubMed

Karch SB, Stephens BG, Ho CH: Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci. 1999, 44: 359-368.CrossRefPubMed

Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA: Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med. 2003, 24: 369-373. 10.1016/S0736-4679(03)00031-3.CrossRefPubMed

Wijetunga M, Bhan R, Lindsay J, Karch S: Acute coronary syndrome and crystal methamphetamine use: a case series. Hawaii Med J. 2004, 63: 8-13.PubMed

Srikanth S, Barua R, Ambrose J: Methamphetamine-associated acute left ventricular dysfunction: a variant of stress-induced cardiomyopathy. Cardiology. 2008, 109: 188-192. 10.1159/000106681.CrossRefPubMed

Jacobs LJ: Reversible dilated cardiomyopathy induced by methamphetamine. Clin Cardiol. 1989, 12: 725-727. 10.1002/clc.4960121211.CrossRefPubMed

Hong R, Matsuyama E, Nur K: Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA. 1991, 265: 1152-1154. 10.1001/jama.265.9.1152.CrossRefPubMed

10.

Maeno Y, Iwasa M, Inoue H, Koyama H, Matoba R: Methamphetamine induces an increase in cell size and reorganization of myofibrils in cultured adult rat cardiomyocytes. Int J Legal Med. 2000, 113: 201-207. 10.1007/s004149900088.CrossRefPubMed

11.

Islam MN, Kuroki H, Hongcheng B, Ogura Y, Kawaguchi N, Onishi S, Wakasugi C: Cardiac lesions and their reversibility after long term administration of methamphetamine. Forensic Sci Int. 1995, 75: 29-43. 10.1016/0379-0738(95)01765-B.CrossRefPubMed

12.

He SY, Matoba R, Fujitani N, Sodesaki K, Onishi S: Cardiac muscle lesions associated with chronic administration of methamphetamine in rats. Am J Forensic Med Pathol. 1996, 17: 155-162. 10.1097/00000433-199606000-00014.CrossRefPubMed

13.

McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, Pennell DJ: Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003, 108: 54-59. 10.1161/01.CIR.0000078641.19365.4C.CrossRefPubMed

14.

Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ: Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005, 26: 1461-1474. 10.1093/eurheartj/ehi258.CrossRefPubMed

15.

Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, Lai S, Bluemke DA, Gerstenblith G, Marban E, Tomaselli GF, Lima JA: Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008, 51: 2414-2421. 10.1016/j.jacc.2008.03.018.PubMedCentralCrossRefPubMed

16.

Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM: The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000, 343: 1445-1453. 10.1056/NEJM200011163432003.CrossRefPubMed

17.

Seiden LS, Sabol KE: Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr. 1996, 163: 251-276.PubMed

18.

Tamura A, Kawano Y, Watanabe T, Aso T, Abe Y, Yano S, Kadota J: A report of 2 cases of transient mid-ventricular ballooning. Int J Cardiol. 2007, 122: e10-12. 10.1016/j.ijcard.2006.11.060.CrossRefPubMed

19.

Hernandez-Pampaloni M, Bax JJ, Morita K, Dutka DP, Camici PG: Incidence of stunned, hibernating and scarred myocardium in ischaemic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2005, 32: 314-321. 10.1007/s00259-004-1682-y.CrossRefPubMed

20.

Bello D, Shah DJ, Farah GM, Di Luzio S, Parker M, Johnson MR, Cotts WG, Klocke FJ, Bonow RO, Judd RM, Gheorghiade M, Kim RJ: Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation. 2003, 108: 1945-1953. 10.1161/01.CIR.0000095029.57483.60.CrossRefPubMed

Title: Recovery of methamphetamine associated cardiomyopathy predicted by late gadolinium enhanced cardiovascular magnetic resonance
Authors: Javier E Lopez
Khung Yeo
Gary Caputo
Michael Buonocore
Saul Schaefer
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Journal of Cardiovascular Magnetic Resonance / Issue 1/2009
Electronic ISSN: 1532-429X
DOI: https://doi.org/10.1186/1532-429X-11-46

At a glance: The STEP trials

Springer Medicine

Recovery of methamphetamine associated cardiomyopathy predicted by late gadolinium enhanced cardiovascular magnetic resonance

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Adverse effect of increased left ventricular wall thickness on five year outcomes of patients with negative dobutamine stress

Quantification of late gadolinium enhanced CMR in viability assessment in chronic ischemic heart disease: a comparison to functional outcome

The added value of longitudinal black-blood cardiovascular magnetic resonance angiography in the cross sectional identification of carotid atherosclerotic ulceration

Determinants of left ventricular mass in obesity; a cardiovascular magnetic resonance study

Effects of deep sedation or general anesthesia on cardiac function in mice undergoing cardiovascular magnetic resonance

Dressler's syndrome demonstrated by late gadolinium enhancement cardiovascular magnetic resonance